Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Respiratory Infection Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Digital Applications to Monitor Novel Coronavirus Disease and Response in Colombia - Syndromic and Vaccination Surveillance

NCT05764174
View directory record Official record
Conditions
Vaccination Refusal, COVID-19
Interventions
Factual messages, Narrative message, Mixed message
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
2,409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 25, 2026, 1:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Diesel Exhaust Followed by Administration of Nasal Spray Flu Vaccine on Individuals With & Without Allergies

NCT00617110
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
live attenuated influenza virus (LAIV) with clean air, LAIV and diesel exhaust particles
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 25, 2026, 1:39 PM EDT
Withdrawn Phase 2 Interventional

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

NCT04725110
View directory record Official record
Conditions
Covid19, SARS-CoV Infection, ARDS, ARDS, Human
Interventions
Instilled T3, Placebo Therapy
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 25, 2026, 1:39 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Trivalent rHA Dose Escalation Study in Elderly Subjects

NCT00170443
View directory record Official record
Conditions
Influenza
Interventions
rHAO Trivalent Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years to 80 Years
Enrollment
399 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2004
U.S. locations
3
States / cities
Rochester, New York • Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Sep 25, 2026, 1:39 PM EDT
Withdrawn Phase 3 Interventional

REVERSE-Long COVID-19 With Baricitinib Study

NCT05858515
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
Baricitinib 4 MG, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 25, 2026, 1:39 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States

NCT06633835
View directory record Official record
Conditions
COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
Interventions
protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 25, 2026, 1:39 PM EDT
Recruiting Phase 3 Interventional

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

NCT05848713
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Heparin
Drug
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Chicago, Illinois • Jefferson, Louisiana • Portland, Maine + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 25, 2026, 1:39 PM EDT
Completed Not applicable Interventional Results available

Reducing Length of Stay for Veterans Hospitalized With Pneumonia

NCT01068548
View directory record Official record
Conditions
Pneumonia
Interventions
reminder
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 25, 2026, 1:39 PM EDT
Completed No phase listed Observational

Role of OMT in the Management of the Persistent Post-COVID-19 Symptoms

NCT06016543
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
osteopathic manipulative treatment (OMT)
Procedure
Lead sponsor
A.T. Still University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kirksville, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 25, 2026, 1:39 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Throat Spray on the Incidence and Duration of Sickness

NCT07246850
View directory record Official record
Conditions
Sore-throat, Common Cold
Interventions
Beekeeper's Propolis Throat Spray, Placebo Throat Spray
Dietary Supplement
Lead sponsor
Beekeeper's Naturals Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 25, 2026, 1:39 PM EDT
Completed Phase 2 Interventional

Phase 2 Study - Erdosteine in Patients With CB/COPD

NCT00338507
View directory record Official record
Conditions
Chronic Bronchitis, Chronic Obstructive Pulmonary Disease
Interventions
Erdosteine
Drug
Lead sponsor
Adams Respiratory Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Sep 25, 2026, 1:39 PM EDT
Completed No phase listed Observational

Pilot Test of COVID-19 Related Clinical Outcome Assessment Methodology and Qualitative Evidence of Content Validity

NCT05207293
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Synairgen Research Ltd.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 25, 2026, 1:39 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

NCT02214225
View directory record Official record
Conditions
Influenza, Human
Interventions
Quadrivalent Influenza Vaccine (QIV), Trivalent Influenza Vaccine (TIV-1), Trivalent Influenza Vaccine (TIV-2)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
3,484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
33
States / cities
Huntsville, Alabama • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 25, 2026, 1:39 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Preparedness Through Respiratory Virus Epidemiology and Community Engagement

NCT07147517
View directory record Official record
Conditions
Respiratory Infection Virus, COVID -19, RSV, FLU
Interventions
Component A0, Component A1, Component A2, Component B
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
25,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
2
States / cities
La Jolla, California • San Ysidro, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 25, 2026, 1:39 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza

NCT05052697
View directory record Official record
Conditions
Influenza, Human
Interventions
mIRV, bIRV AB, qIRV, QIV, bIRV AA, bIRV BB
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
100
States / cities
Athens, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 25, 2026, 1:39 PM EDT
Withdrawn Phase 2 Interventional

Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms

NCT04734860
View directory record Official record
Conditions
Covid19
Interventions
COVI-AMG, Placebo
Biological · Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Garden Grove, California • Bradenton, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 25, 2026, 1:39 PM EDT
Completed No phase listed Observational

Sinusitis in Children and the Nasopharyngeal Microbiome

NCT01492868
View directory record Official record
Conditions
Sinusitis
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
4 Years to 7 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 25, 2026, 1:39 PM EDT
Completed Not applicable Interventional

Exercise in Adults with Post-Acute Sequelae of SARS-CoV-2 (COVID-19) Infection Study

NCT05218174
View directory record Official record
Conditions
COVID-19
Interventions
Exercise Prescription
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Frisco, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Sep 25, 2026, 1:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pandemic-adapted Caries Care Multicentre Single-group Interventional Study

NCT04666597
View directory record Official record
Conditions
Dental Caries in Children
Interventions
Modified CariesCare International management
Procedure
Lead sponsor
Universidad El Bosque, Bogotá
Other
Eligibility
3 Years to 8 Years
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 25, 2026, 1:39 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A/Texas Flu Challenge

NCT06753474
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus influenza A H3N2 strain
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 25, 2026, 1:39 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

NCT05833217
View directory record Official record
Conditions
Long COVID, Insulin Resistance, Insulin Sensitivity
Interventions
Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test
Procedure · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 25, 2026, 1:39 PM EDT
Withdrawn Phase 3 Interventional

Outpatient Use of Ivermectin in COVID-19

NCT04530474
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin Pill, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Sep 25, 2026, 1:39 PM EDT
Completed No phase listed Observational Results available

Collection and Testing of Respiratory Samples

NCT01302418
View directory record Official record
Conditions
QIAGEN ResPlex II Advanced Panel, Influenza A, Respiratory Syncytial Virus Infections, Infection Due to Human Parainfluenza Virus 1, Parainfluenza Type 2, Parainfluenza Type 3, Parainfluenza Type 4, Human Metapneumovirus A/B, Rhinovirus, Coxsackie Virus/Echovirus, Adenovirus Types B/C/E, Coronavirus Subtypes 229E, Coronavirus Subtype NL63, Coronavirus Subtype OC43, Coronavirus Subtype HKU1, Human Bocavirus, Artus Influenza A/B RT-PCR Test, Influenza B
Interventions
artus Influenza A/B RT-PCR Test
Device
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
Not listed
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Tuscon, Arizona • Albany, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 25, 2026, 1:39 PM EDT